• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Accuray Reports Fiscal 2025 Third Quarter Financial Results

    4/30/25 4:05:00 PM ET
    $ARAY
    Medical/Dental Instruments
    Health Care
    Get the next $ARAY alert in real time by email

    MADISON, Wis., April 30, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the third quarter ended March 31, 2025.

    Accuray Incorporated (PRNewsFoto/Accuray Incorporated) (PRNewsFoto/Accuray Incorporated)

    Key Fiscal Third Quarter Highlights:

    • Total net revenue was $113.2 million, an increase of 12 percent year-over-year
    • Net loss was $1.3 million compared to a net loss of $6.3 million in the prior year period
    • Adjusted EBITDA was $6.0 million compared to $1.1 million in the prior year period

    "We achieved a strong third quarter and I am proud of the resiliency of the entire team and their focus on driving actions to mitigate the impact of the tariffs. Despite evolving global dynamics, our team's disciplined execution, clear strategy and the growing underlying demand for our innovative, distinct technologies gives us confidence in our ability to deliver sustained performance," said Suzanne Winter, CEO of Accuray.

    Fiscal Third Quarter Results



    Total net revenue in the third quarter of fiscal 2025 increased to $113.2 million, an increase of 12 percent, from $101.1 million in the prior fiscal year third quarter. Product revenue in the third quarter of fiscal 2025 increased to $57.3 million, an increase of 16 percent, from $49.6 million in the prior fiscal year third quarter. Service revenue in the third quarter of fiscal 2025 increased to $55.9 million, an increase of 9 percent, from $51.5 million in the prior fiscal year third quarter.

    Total gross profit in the third quarter of fiscal 2025 increased to $31.6 million, or 27.9 percent of total net revenue, compared to a total gross profit of $29.1 million, or 28.7 percent of total net revenue, in the prior fiscal year third quarter.

    Operating expenses in the third quarter of fiscal 2025 decreased to $30.6 million, a decrease of 9 percent, from $33.6 million in the prior fiscal year third quarter.



    Net loss in the third quarter of fiscal 2025 was $1.3 million, or $0.01 per share, compared to a net loss of $6.3 million, or $0.06 per share, in the prior fiscal year third quarter. Adjusted EBITDA in the third quarter of fiscal 2025 was $6.0 million, compared to $1.1 million in the prior fiscal year third quarter.

    Gross product orders in the third quarter of fiscal 2025 decreased to $71.2 million from $89.1 million in the prior fiscal year third quarter. The book to bill ratio was 1.2 in the third quarter of fiscal 2025, compared to a book to bill ratio of 1.8 in the prior fiscal year third quarter. Order backlog as of March 31, 2025 was $452.4 million, which is approximately 10 percent lower than at the end of the prior fiscal year third quarter.

    Cash, cash equivalents, and short-term restricted cash were $78.8 million as of March 31, 2025, an increase of $14.8 million from December 31, 2024 and a $9.8 million decrease from June 30, 2024.

    Fiscal Nine Months Results

    Total net revenue in the first nine months of fiscal 2025 increased to $331.0 million, an increase of 6 percent, from $312.3 million in the prior fiscal year period. Product revenue in the first nine months of fiscal 2025 increased to $166.9 million, an increase of 8 percent, from $154.5 million in the prior fiscal year period. Service revenue in the first nine months of fiscal 2025 increased to $164.1 million, an increase of 4 percent, from $157.8 million in the prior fiscal year period.

    Total gross profit in the first nine months of fiscal 2025 increased to $108.0 million, or 32.6 percent of total net revenue, as compared to total gross profit of $104.5 million, or 33.5 percent of total net revenue, in the prior fiscal year period.

    Operating expenses in the first nine months of fiscal 2025 decreased to $104.4 million, a decrease of 6 percent, from $110.8 million in the prior fiscal year period.

    Net loss in the first nine months of fiscal 2025 was $2.7 million, or $0.03 per share, compared to a net loss of $18.9 million, or $0.19 per share, in the prior fiscal year period. Adjusted EBITDA in the first nine months of fiscal 2025 was $18.8 million, compared to $9.6 million in the prior fiscal year period.

    Gross product orders in the first nine months of fiscal 2025 decreased to $203.3 million from $246.7 million in the prior fiscal year period. The book to bill ratio was 1.2 in the first nine months of fiscal 2025, compared to a book to bill ratio of 1.6 in the same period in the prior fiscal year period.

    Fiscal Year 2025 Financial Guidance

    The Company is reaffirming adjusted EBITDA guidance for fiscal year 2025 as follows:.

    • Adjusted EBITDA is expected in the range of $28.5 million to $31.0 million.

    Due to the recent tariff announcements and the estimated impact to product volume, the company is adjusting revenue guidance for the fiscal year 2025 as follows:

    • Total revenue is expected in the range of $452 million to $460 million.

    Guidance for non-GAAP financial measures excludes depreciation and amortization, stock-based compensation, interest expense, and provision for income taxes. For more information regarding the non-GAAP financial measures discussed in this press release, please see "Use of Non-GAAP Financial Measures" below.

    Conference Call Information

    Accuray will host a conference call beginning at 1:30 p.m. PT/4:30 p.m. ET today to discuss results for the third quarter of fiscal 2025 as well as recent corporate developments. Conference call dial-in information is as follows:

    • U.S. callers: (833) 316-0563
    • International callers: (412) 317-5747

    Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Investor Relations section of Accuray's website, www.accuray.com. There will be a slide presentation accompanying today's event which can also be accessed on the company's Investor Relations page at www.accuray.com.

    In addition, a taped replay of the conference call will be available beginning approximately one hour after the call's conclusion and will be available for seven days. The replay number is (877) 344-7529 (USA), or (412) 317-0088 (International), Conference ID: 8141169. An archived webcast will also be available on Accuray's website until Accuray announces its results for the fourth quarter of fiscal 2025.

    Use of Non-GAAP Financial Measures

    Accuray reports its financial results in accordance with generally accepted accounting principles in the United States ("GAAP") and the rules of the SEC. To supplement its financial statements prepared and presented in accordance with GAAP, Accuray uses certain non-GAAP financial measures, such as adjusted EBITDA.

    Accuray has supplemented its GAAP net income (loss) with a non-GAAP measure of adjusted earnings before interest, taxes, depreciation, amortization, stock-based compensation, restructuring charges and ERP and ERP related expenditures. ("adjusted EBITDA"). The calculation of adjusted EBITDA also excludes certain non-recurring, irregular and one-time items. Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the company and facilitates a meaningful comparison of results for current periods with previous operating results. A reconciliation of GAAP net loss (the most directly comparable GAAP measure) to non-GAAP adjusted EBITDA is provided in the schedules below.

    There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the company's consolidated financial statements prepared in accordance with GAAP.

    About Accuray

    Accuray Incorporated (NASDAQ:ARAY) is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide.

    Safe Harbor Statement

    Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the company's guidance and future results of operations, including expectations regarding: total revenue and adjusted EBITDA; the company's ability to deliver sustained performance and execute on its strategies;  expectations regarding the impact of tariffs as well as mitigation efforts by the company; the company's ability to navigate supply chain, logistics, macroeconomic, and foreign exchange challenges; the company's expectations regarding its capital structure and refinancing needs; the company's ability to achieve its longer-term goals; expectations regarding the company's China joint venture; expectations related to the amount and timing of realizing deferred margin from the company's China joint venture; expectations with respect to strategic partnerships and collaborations; expectations related to the markets and regions in which the company operates; expectations regarding new product introductions and innovations; expectations regarding service business growth and its ability to serve as a growth driver; and the company's ability to advance patient care and offer value to its customer. These forward-looking statements involve risks and uncertainties. If any of these risk or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results express or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the effect of the global macroeconomic environment on the operations of the company and those of its customers and suppliers; disruptions to our supply chain, including increased logistics costs; the company's ability to achieve widespread market acceptance of its products; the company's ability to refinance its debt; the effect of enhanced international tariffs on the company; the company's ability to realize the expected benefits of the China joint venture and other partnerships; risks inherent in international operations; the company's ability to maintain or increase its gross margins on product sales and services; delays in regulatory approvals or the development or release of new offerings; the company's ability to meet the covenants under its credit facilities; the company's ability to convert backlog to revenue; and such other risks identified under the heading "Risk Factors" in the company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on February 5, 2025, and as updated periodically with the company's other filings with the SEC.

    Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

    Aman Patel, CFA

    Beth Kaplan

    Investor Relations, ICR-Westwicke

    Public Relations Director, Accuray

    +1 (443) 450-4191

    +1 (408) 789-4426

    [email protected]

    [email protected]

    Financial Tables to Follow

     

    Accuray Incorporated

    Condensed Consolidated Statements of Operations

    (in thousands, except per share data)

    (Unaudited)







    Three Months Ended

    March 31,





    Nine Months Ended

    March 31,







    2025





    2024





    2025





    2024



    Net revenue:

























    Products



    $

    57,320





    $

    49,603





    $

    166,878





    $

    154,491



    Services





    55,923







    51,529







    164,084







    157,771



    Total net revenue





    113,243







    101,132







    330,962







    312,262



    Cost of revenue:

























    Cost of products





    44,301







    35,945







    111,315







    105,977



    Cost of services





    37,315







    36,113







    111,659







    101,816



    Total cost of revenue





    81,616







    72,058







    222,974







    207,793



    Gross profit





    31,627







    29,074







    107,988







    104,469



    Operating expenses:

























    Research and development





    10,712







    10,909







    36,472







    40,203



    Selling and marketing





    9,110







    10,318







    31,906







    31,923



    General and administrative





    10,758







    12,409







    36,005







    38,656



    Total operating expenses





    30,580







    33,636







    104,383







    110,782



    Income (loss) from operations





    1,047







    (4,562)







    3,605







    (6,313)



    Income from equity method investment, net





    2,297







    1,024







    3,829







    1,028



    Interest expense





    (2,890)







    (2,884)







    (8,728)







    (8,728)



    Other income (expense), net





    (1,294)







    524







    357







    (1,665)



    Loss before provision for income taxes





    (840)







    (5,898)







    (937)







    (15,678)



    Provision for income taxes





    457







    444







    1,777







    3,254



    Net loss



    $

    (1,297)





    $

    (6,342)





    $

    (2,714)





    $

    (18,932)



    Net loss per share - basic and diluted



    $

    (0.01)





    $

    (0.06)





    $

    (0.03)





    $

    (0.19)



    Weighted average common shares used in computing net loss per share:

























    Basic and diluted





    102,825







    99,197







    101,462







    97,838



     

    Accuray Incorporated

    Condensed Consolidated Balance Sheets

    (in thousands)

    (Unaudited)







    March 31,





    June 30,







    2025





    2024



    Assets













    Current assets:













    Cash and cash equivalents



    $

    77,824





    $

    68,570



    Restricted cash





    1,013







    485



    Accounts receivable, net





    78,191







    92,001



    Inventories, net





    146,445







    138,324



    Prepaid expenses and other current assets





    29,203







    23,006



    Deferred cost of revenue





    782







    850



    Total current assets





    333,458







    323,236



    Property and equipment, net





    27,081







    24,774



    Investment in joint venture





    9,284







    9,826



    Operating lease right-of-use assets, net





    34,023







    33,773



    Goodwill





    57,720







    57,672



    Long-term restricted cash





    1,407







    1,337



    Other assets





    21,318







    18,009



    Total assets



    $

    484,291





    $

    468,627



    Liabilities and stockholders' equity













    Current liabilities:













    Accounts payable



    $

    46,319





    $

    50,020



    Accrued compensation





    13,413







    17,128



    Operating lease liabilities, current





    7,233







    6,218



    Other accrued liabilities





    34,943







    28,508



    Customer advances





    12,194







    13,988



    Deferred revenue





    81,753







    71,649



    Short-term debt





    7,574







    7,756



    Total current liabilities





    203,429







    195,267



    Operating lease liabilities, non-current





    33,352







    32,373



    Long-term other liabilities





    6,127







    7,389



    Deferred revenue, non-current





    25,591







    24,114



    Long-term debt





    166,209







    164,400



    Total liabilities





    434,708







    423,543



    Stockholders' equity:













    Common stock





    103







    100



    Additional paid-in capital





    575,032







    566,887



    Accumulated other comprehensive loss





    (5,157)







    (4,222)



    Accumulated deficit





    (520,395)







    (517,681)



    Total stockholders' equity





    49,583







    45,084



    Total liabilities and stockholders' equity



    $

    484,291





    $

    468,627



     

    Accuray Incorporated

    Summary of Orders and Backlog

    (in thousands, except book to bill ratio)

    (Unaudited)







    Three Months Ended

    March 31,





    Nine Months Ended

    March 31,







    2025





    2024





    2025





    2024



    Gross orders



    $

    71,167





    $

    89,086





    $

    203,294





    $

    246,676



    Net orders





    46,656







    60,795







    131,951







    147,141



    Order backlog





    452,392







    503,220







    452,392







    503,220



    Book to bill ratio (a)





    1.2







    1.8







    1.2







    1.6





    (a) Book to bill ratio is defined as gross orders for the period divided by product revenue for the period.

     

    Accuray Incorporated

    Reconciliation of GAAP Net Loss to Adjusted EBITDA

    (in thousands)

    (Unaudited)







    Three Months Ended

    March 31,





    Nine Months Ended

    March 31,







    2025





    2024





    2025





    2024



    GAAP net loss



    $

    (1,297)





    $

    (6,342)





    $

    (2,714)





    $

    (18,932)



    Depreciation and amortization (a)





    1,575







    1,601







    4,552







    4,398



    Stock-based compensation





    2,745







    2,735







    7,383







    7,441



    Interest expense, net (b)





    2,568







    2,649







    7,825







    7,990



    Provision for income taxes





    457







    444







    1,777







    3,254



    Restructuring charges





    —







    —







    —







    2,633



    ERP and ERP related expenditures





    —







    —







    —







    2,815



    Adjusted EBITDA



    $

    6,048





    $

    1,087





    $

    18,823





    $

    9,599





    (a) Consists of depreciation on property and equipment and amortization of intangibles.

    (b) Consists of interest expense net of interest income.

     

    Accuray Incorporated

    Forward-Looking Guidance

    Reconciliation of Projected GAAP Net Loss to Projected Adjusted EBITDA

    (in thousands)

    (Unaudited)







    Twelve Months Ending

    June 30, 2025







    From





    To



    GAAP net loss



    $

    (4,000)





    $

    (1,500)



    Depreciation and amortization (a)





    6,500







    6,500



    Stock-based compensation





    10,000







    10,000



    Interest expense, net (b)





    13,000







    13,000



    Provision for income taxes





    3,000







    3,000



    Adjusted EBITDA



    $

    28,500





    $

    31,000





    (a) Consists of depreciation on property and equipment and amortization of intangibles.

    (b) Consists of interest expense net of interest income.

     

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-reports-fiscal-2025-third-quarter-financial-results-302443104.html

    SOURCE Accuray Incorporated

    Get the next $ARAY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARAY

    DatePrice TargetRatingAnalyst
    2/13/2024$9.00Buy
    ROTH MKM
    6/23/2022$7.50Buy
    B. Riley Securities
    12/22/2021$7.50Buy
    Loop Capital
    More analyst ratings

    $ARAY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Accuray to Participate in the Jefferies Global Healthcare Conference 2025

      MADISON, Wis., May 29, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today its participation in the Jefferies Global Healthcare Conference 2025. The management team is scheduled to participate in a fireside chat on Wednesday, June 4th, 2025, at 5:30pm EDT/2:30pm PDT. A live webcast of the call will also be available from the Investor Relations section of the company's website at investors.accuray.com. A webcast replay can be accessed on the website and will remain available for 90 days. About AccurayAccuray is committed to expanding the powerful potential o

      5/29/25 7:30:00 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Accuray Showcases New Long-Term Data¹ on Benefits of 5 Session Radiotherapy Treatment for Men with Prostate Cancer at ESTRO 2025

      More than 40 Clinical Studies Using Accuray Technology Presented at ESTRO 2025; Company Highlights Innovation and Educational Symposia MADISON, Wis., May 7, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that new data presented at the European Society for Radiotherapy and Oncology (ESTRO) meeting reinforces the benefits of the company's CyberKnife® System in the treatment of prostate cancer at multiple stages of the cancer journey. The studies, shared at the annual congress held in Vienna, Austria, indicate the system's accuracy and precision enable treatment of high-risk disease, as well as recurrent prostate cancer following prostatectomy, with stereotactic body r

      5/7/25 7:35:00 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Accuray Announces First SRS/SBRT Patient Treatments in Austria With the CyberKnife® System

      Medical Team's Use of Accuray CyberComm™ Reduced Commissioning Time by Approximately 50 Percent*, Enabling Them to Initiate Patient Treatments Sooner MADISON, Wis., May 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that the CyberKnife® Center Salzburg is the first in Austria to treat patients with the CyberKnife® System, expanding access to stereotactic radiosurgery (SRS) and ultra-hypofractionated stereotactic body radiation therapy (SBRT), treatment processes necessitating an extremely high degree of precision and accuracy. The CyberKnife Center Salzburg's team used the Accuray CyberComm™ technology to commission their system, the latest-generation CyberKnife S

      5/5/25 4:10:00 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Accuray with a new price target

      ROTH MKM initiated coverage of Accuray with a rating of Buy and set a new price target of $9.00

      2/13/24 6:29:42 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • B. Riley Securities initiated coverage on Accuray with a new price target

      B. Riley Securities initiated coverage of Accuray with a rating of Buy and set a new price target of $7.50

      6/23/22 7:25:39 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Loop Capital initiated coverage on Accuray with a new price target

      Loop Capital initiated coverage of Accuray with a rating of Buy and set a new price target of $7.50

      12/22/21 4:56:14 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    SEC Filings

    See more
    • SEC Form SD filed by Accuray Incorporated

      SD - ACCURAY INC (0001138723) (Filer)

      5/30/25 4:01:08 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Accuray Incorporated

      10-Q - ACCURAY INC (0001138723) (Filer)

      5/2/25 4:05:24 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Accuray Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - ACCURAY INC (0001138723) (Filer)

      4/30/25 4:10:13 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    Leadership Updates

    Live Leadership Updates

    See more
    • Leonel Peralta to Join Accuray as Chief Operations Officer

      MADISON, Wis., Jan. 21, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that Leonel Peralta is joining the company as Senior Vice President, Chief Operations Officer, effective February 3, 2025. Mr. Peralta will be responsible for leading worldwide manufacturing operations including driving alignment of operations with corporate business goals, maximizing supply chain profitability and efficiency, and ensuring processes support best-in-class customer service. He will report to Accuray President and Chief Executive Officer Suzanne Winter. Mr. Peralta has

      1/21/25 9:15:00 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Accuray Appoints Michael Murphy as VP, Corporate Controller

      MADISON, Wis., Oct. 21, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today that Michael Murphy, CPA has joined the company as Vice President, Corporate Controller. Mr. Murphy will be responsible for leading the global accounting function including corporate tax, regulatory reporting, accounting policies, and risk management, along with associated budgetary and administrative operations. He will report to Accuray Senior Vice President & Chief Financial Officer Ali Pervaiz. The company also expects to appoint Mr. Murphy to the position of principal accounting officer following the filing of the company's quarterly report on Form 10-Q for the period ended September 30, 2024

      10/21/24 4:05:00 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Robert C. Kill Joins Accuray Board of Directors

      SUNNYVALE, Calif., Feb. 1, 2023 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) announced today the appointment of Robert C. Kill to the company's Board of Directors, effective as of January 30, 2023. Mr. Kill is a skilled healthcare executive with more than 30 years' experience transforming various healthcare-related companies. In his most recent executive position as CEO of Parata Systems, Mr. Kill grew company revenue over 5X during his tenure before it sold last year for more than $1.5 billion. Before Parata, Mr. Kill was affiliated with two private equity funds, Frazie

      2/1/23 4:10:00 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Accuray Incorporated

      SC 13G/A - ACCURAY INC (0001138723) (Subject)

      9/6/24 9:00:07 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Accuray Incorporated

      SC 13G - ACCURAY INC (0001138723) (Subject)

      2/13/24 4:56:01 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Accuray Incorporated (Amendment)

      SC 13G/A - ACCURAY INC (0001138723) (Subject)

      2/13/24 11:19:22 AM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by SVP, Chief Operations Officer Peralta Leonel

      4 - ACCURAY INC (0001138723) (Issuer)

      3/3/25 5:41:56 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • SEC Form 3 filed by new insider Peralta Leonel

      3 - ACCURAY INC (0001138723) (Issuer)

      2/13/25 4:10:11 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • SVP Chief Financial Officer Pervaiz Ali covered exercise/tax liability with 2,013 shares, decreasing direct ownership by 0.55% to 362,231 units (SEC Form 4)

      4 - ACCURAY INC (0001138723) (Issuer)

      1/2/25 5:32:36 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Whitters Joseph E bought $156,045 worth of shares (100,000 units at $1.56), increasing direct ownership by 22% to 561,053 units (SEC Form 4)

      4 - ACCURAY INC (0001138723) (Issuer)

      5/30/24 4:10:11 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care

    $ARAY
    Financials

    Live finance-specific insights

    See more
    • Accuray Reports Fiscal 2025 Third Quarter Financial Results

      MADISON, Wis., April 30, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the third quarter ended March 31, 2025. Key Fiscal Third Quarter Highlights: Total net revenue was $113.2 million, an increase of 12 percent year-over-yearNet loss was $1.3 million compared to a net loss of $6.3 million in the prior year periodAdjusted EBITDA was $6.0 million compared to $1.1 million in the prior year period"We achieved a strong third quarter and I am proud of the resiliency of the entire team and their focus on driving actions to mitigate the

      4/30/25 4:05:00 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Accuray to Report Third Quarter Fiscal 2025 Financial Results on April 30, 2025

      MADISON, Wis., April 16, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) will report financial results for the third quarter of fiscal year 2025, ended March 31, 2025, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on April 30, 2025. The conference call dial-in numbers are 1-833-316-0563 (USA) or 1-412-317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one week. The replay number is 1-877-344-7529 (USA) or 1-412-317-0088 (internationa

      4/16/25 4:05:00 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care
    • Accuray Reports Strong Fiscal 2025 Second Quarter Financial Results & Raises Guidance

      MADISON, Wis., Feb. 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ:ARAY) today reported financial results for the second quarter ended December 31, 2024. Key Fiscal Q2 Highlights: Strong second quarter and first half results; raising fiscal year 2025 guidanceTotal net revenue was $116.2 million, an increase of 8 percent year-over-yearNet income was $2.5 million compared to a net loss of $9.6 million in the prior year periodAdjusted EBITDA was $9.6 million compared to $2.0 million in the prior year period"Our strong Q2 performance reflects outstanding execution of our str

      2/5/25 4:05:00 PM ET
      $ARAY
      Medical/Dental Instruments
      Health Care